Literature DB >> 1900357

A potential role for c-jun in cell cycle progression through late G1 and S.

R Carter1, S C Cosenza, A Pena, K Lipson, D R Soprano, K J Soprano.   

Abstract

When the level of c-jun mRNA was analyzed in WI-38 human fibroblasts exciting short- and long-term quiescence, two peaks of c-jun mRNA accumulation were found. The first occurred one hour after stimulation and lasted three to five hours, whereas the second occurred at the G1/S border and was coupled to the time of entry to S phase rather than to the time of stimulation. The early peak is well documented and in agreement with the proposed role of c-Jun/AP-1 in mediating cellular responses to receptor-generated signals. The later peak, however, has not been previously reported. Additional follow-up studies showed that late G1/S expression was not solely a phenomenon of cells existing a quiescent state, nor was it restricted only to human cells. Gel retardation studies confirmed that there is AP-1 specific DNA binding activity in nuclear extracts isolated in late G1 and S phase, and that this AP-1 binding activity is due to the presence of Jun protein. An anti-Fos antibody was able to significantly decrease AB-1 binding activity in early G1 extracts, but had no effect on extracts isolated in late G1 and S phase, indicating that the complexes observed in late G1 and S phase are clearly different from those seen in early G1. These studies are among the first to suggest a functional dissociation of c-Jun from c-Fos. Our results identify a new, previously unreported role for c-Jun/AP-1 in regulation of cell cycle progression and mammalian cell growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900357

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes.

Authors:  F Thierry; G Spyrou; M Yaniv; P Howley
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5.

Authors:  M J Marinissen; M Chiariello; M Pallante; J S Gutkind
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

3.  BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C.

Authors:  Y Kato; V V Kravchenko; R I Tapping; J Han; R J Ulevitch; J D Lee
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

4.  MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src.

Authors:  Weiyong Sun; Xudong Wei; Kamala Kesavan; Timothy P Garrington; Ruihua Fan; Junjie Mei; Steven M Anderson; Erwin W Gelfand; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

5.  Different binding specificities and transactivation of variant CRE's by CREB complexes.

Authors:  D M Benbrook; N C Jones
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

6.  Induction of junB expression, but not c-jun, by granulocyte colony-stimulating factor or macrophage colony-stimulating factor in the proliferative response of human myeloid leukemia cells.

Authors:  K Adachi; H Saito
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

7.  Jun is phosphorylated by several protein kinases at the same sites that are modified in serum-stimulated fibroblasts.

Authors:  S J Baker; T K Kerppola; D Luk; M T Vandenberg; D R Marshak; T Curran; C Abate
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

8.  Identification of a 68 kDa protein species as a specific DNA-binding component of the H3abp complex interacting with the histone H3.2 G1/S regulatory domain.

Authors:  G S Naeve; Y Zhou; A S Lee
Journal:  Nucleic Acids Res       Date:  1995-02-11       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.